A recent article highlighted Abbott Laboratories as one of the 10 stocks defying market uncertainties. Abbott's stock rose by 3.74% due to a rating upgrade from Oppenheimer, fueled by the company's CE Mark approval in Europe for its Volt PFA catheter.